01
Cash & equivalents decreased 66.2%
Cash & equivalents changed -66.2% from the comparable as-filed period.
$23.8M→$8.1MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSkye Bioscience, Inc.'s latest supported as-filed period reports net income of -$10.8M, 38.8% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -66.2% from the comparable as-filed period.
Net income changed +38.8% from the comparable as-filed period.
Operating income changed +39.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SKYE · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-058605SEC ↗4Aug 20, 2026Period Aug 18, 20260001598549-26-000005SEC ↗4Aug 20, 2026Period Aug 18, 20260001231919-26-000959SEC ↗8-K/AAug 20, 2026Period Aug 12, 20260001628280-26-058120SEC ↗8-KAug 19, 2026Period Aug 18, 20260001628280-26-057804SEC ↗10-QAug 14, 2026Period Jun 30, 20260001628280-26-056968SEC ↗8-KAug 14, 2026Period Aug 12, 20260001628280-26-056966SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 1,159 | $0 | $371 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 46 | $0 | $15 | Form 4 ↗ |
| Aug 20, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 6,495 | $0 | $2,078 | Form 4 ↗ |
| Aug 19, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 10,255 | $0 | $3,589 | Form 4 ↗ |
| Aug 19, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Stock-based compensation changed -37.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-054941| Schwab Andrew J.Director |
| Open Market SaleIndirect |
| 409 |
| $0 |
| $143 |
| Form 4 ↗ |
| Aug 19, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 57,476 | $0 | $20,117 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 45,090 | $0 | $17,134 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 1,830 | $0 | $695 | Form 4 ↗ |
| Aug 18, 2026Filed Aug 20, 2026 | Schwab Andrew J.Director | Open Market SaleIndirect | 253,080 | $0 | $96,170 | Form 4 ↗ |